Nymox Pharmaceutical Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NYMXF research report →
Price Chart
About the company
Nymox Pharmaceutical Corporation is a biopharmaceutical firm focused on the research and development of medications for the aging population. Operating internationally, including in Canada, the United States, and Europe, the company's flagship drug candidate is Fexapotide Triflutate (NX-1207). This compound is currently undergoing various clinical trials for conditions such as benign prostatic hyperplasia and low-grade localized prostate cancer, with preclinical investigations also underway for hepatocellular carcinoma.
- CEO
- Paul Averback
- IPO
- 1997
- Employees
- 16
- HQ
- Nassau, NW, BS
Get TickerSpark's AI analysis on NYMXF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $18.91K
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- 0.01
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 90.31%
- ROIC
- 63.22%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-1,000+90.9%
- Op Income
- $-4,283,000
- Net Income
- $-4,492,000+49.2%
- EPS
- $-0.05+50.3%
- OCF Growth
- +35.9%
- FCF Growth
- +35.9%
- 52W High
- $0.20
- 52W Low
- $0.00
- 50D MA
- $0.07
- 200D MA
- $0.07
- Beta
- 8.90
- RSI (14)
- 26
- Avg Volume
- 30.95K
No earnings-call transcripts are available for NYMXF yet.
- Free Float
- 59.3%
- Shares Outstanding
- 94.54M
- Float Shares
- 56.10M
Our NYMXF coverage
Recent articles, reports, and earnings notes.
No research on NYMXF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NYMXF report →NYMOX Provides Current Update
accessnewswire.com · Jun 2
NYMOX Provides Recent Updates
accessnewswire.com · Mar 27
Nymox Announces Dismissal of Delaware Action Against Ascella
globenewswire.com · Mar 11
NYMOX Announces Trading Resumed and New Listing on OTCQB Market
globenewswire.com · Dec 17
Nymox Announces Filing of Annual Report
globenewswire.com · Aug 30
Nymox Annual Report
globenewswire.com · Jul 18
Nymox Required to Resubmit Application to DKMA
globenewswire.com · Jul 16
Nymox Reports Victory in Bahamas Litigation Against Terminated Ex-Employees – Court Awards Costs and Damages
globenewswire.com · Mar 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.